AGI May 39/5

Chisholm, Jeffrey W., Patrick Nation, Peter J. Dolphin, and Luis B. Agellon. High plasma cholesterol in drug-induced cholestasis is associated with enhanced hepatic cholesterol synthesis. Am. J. Physiol. 276 (Gastrointest. Liver Physiol. 39): G1165–G1173, 1999.—In a-naphthylisothiocyanate-treated mice, plasma phospholipid (PL) levels were elevated 10and 13-fold at 48 and 168 h, respectively, whereas free cholesterol (FC) levels increased between 48 h (17-fold) and 168 h (39-fold). Nearly all of these lipids were localized to lipoprotein X-like particles in the low-density lipoprotein density range. The PL fatty acyl composition was indicative of biliary origin. Liver cholesterol and PL content were near normal at all time points. Hepatic hydroxymethylglutaryl CoA reductase activity was increased sixfold at 48 h, and cholesterol 7a-hydroxylase activity was decreased by ,70% between 24 and 72 h. These findings suggest a metabolic basis for the appearance of abnormal plasma lipoproteins during cholestasis. Initially, PL and bile acids appear in plasma where they serve to promote the efflux of cholesterol from hepatic cell membranes. Hepatic cholesterol synthesis is then likely stimulated in the response to the depletion of hepatic cell membranes of cholesterol. We speculate that the enhanced synthesis of cholesterol and impaired conversion to bile acids, particularly during the early phase of drug response, contribute to the accumulation of FC in the plasma.